Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS004 + Toripalimab in Advanced RCC
NCT06730932Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tifcemalimab in clear cell renal cell carcinoma (ccRCC), sponsored by Renji Hospital. Primary endpoint: Objective Response Rate up to 2 years. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
tifcemalimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06730932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06730932.